Navigation Links
Milnacipran Demonstrated Significant Improvement in Pain and the Core Symptoms of Fibromyalgia Syndrome, Data Show
Date:11/8/2007

re assessed for all patients at both the three- and six-month visits.

Patients who completed the full six-months of treatment in Study FMS-031 were eligible to enroll in a multi-center, dose-blinded, extension study designed to evaluate durability of response up to one year. A total of 449 patients were either maintained at 200 mg/day (n=209) or re-randomized to 100 mg/day (n=48) or 200 mg/day (n=192) for an additional six months. Efficacy assessments included change in pain, as measured using a paper visual analog scale, and multidimensional symptomatic improvements, as measured using the Fibromyalgia Impact Questionnaire and PGIC.

Data Highlights

Results reported below are based on observed cases, which include only patients who were evaluable at the landmark visit. In study MLN-MD-02, there were 713 evaluable patients for the fibromyalgia syndrome and pain analyses (n=236 for 100 mg, n=215 for 200 mg, and n=262 for placebo).

In study FMS-031, at the three-month visit there were 549 evaluable patients for the syndrome analysis (n=134 for 100 mg, n=259 for 200 mg, and n=156 for placebo), and 553 evaluable patients for the pain analysis (n=135 for 100 mg, n=260 for 200 mg, and n=158 for placebo). At the six-month visit there were 488 evaluable patients for the fibromyalgia syndrome analysis (n=120 for 100 mg, n=229 for 200 mg, and n=139 for placebo), and 491 evaluable patients for the fibromyalgia pain analysis (n=121 for 100 mg, n=230 for 200 mg, and n=140 for placebo).

Composite responder rates for fibromyalgia syndrome (pain, PGIC, and SF-36 PCS)

-- A statistically significant number of patients treated with milnacipran

during Study MLN-MD-02 met the composite syndrome responder criteria

(25% and 26% for the milnacipran 100 mg and 200 mg groups,

respectively) compared to patients treated with placebo (13%).

-- A statistically significant number of patients treated with milnacipran

durin
'/>"/>

SOURCE Forest Laboratories, Inc. and Cypress Bioscience, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
2. Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week
3. Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study
4. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
5. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
6. Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
11. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... ON , Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. ... with a focus on Omega-3 therapies for cardiovascular disease and ... of the Company,s accomplishments in 2014 and its outlook for ... Dear Fellow Shareholders, We would like to ...
(Date:1/22/2015)... (NASDAQ: TECH ) announced today that it ... Simple Plex platform through its Proteins Platform division under ... the previously acquired CyPlex instrument platform from CyVek. ... technology which integrates an innovatively designed microfluidic cartridge with ...
(Date:1/22/2015)... 22, 2015 Increasing sophistication among enterprise buyers of ... purchasing in 2015, says Moravia CMO, ... study by market research firm Common Sense Advisory, 15 ... their translation and localization needs. "From a language industry ...
Breaking Medicine Technology:Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7Bio-Techne Launches Simple Plex Platform 2Bio-Techne Launches Simple Plex Platform 3Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2
... Comprehensive Care Corporation (OTC BB: CHCR), a leading ... provider for managed care companies throughout the U.S., today ... Rx Inc., has been selected as the new President ... the healthcare industry, is a graduate of the United ...
... -- Dehaier Medical Systems Ltd. (Nasdaq: ... leader in the development, assembly, marketing and sale of ... announced that it will release financial results for the ... on Monday, November 14, 2011 before the start of ...
Cached Medicine Technology:Comprehensive Care Corporation Names Robert R. Kulbick New President 2Comprehensive Care Corporation Names Robert R. Kulbick New President 3Dehaier Medical to Report Third Quarter 2011 Financial Results on November 14 2
(Date:1/22/2015)... Yesterday, Senator Holly Mitchell (D-Los ... Olsen (R-Modesto) were honored by the California Healthcare ... biomedical science, medical device and pharmaceutical innovation in ... “2014 Life Sciences Champion” award from CHI President ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative and easy ... treat specific body parts and muscle groups. , IsoComforter, ... use patented cold therapy machine with the innovative IsoTube design ... injuries. IsoComforter has become the industry leader in cold ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Payday lending ... vulnerable communities and cause financial distress to the states ... analysts at Howard University’s Center on Race and Wealth. ... in economic activity, payday loans at the same time ...
(Date:1/22/2015)... January 22, 2015 As interest in the ... care gains momentum worldwide, Rev. Eric J. Hall , ... Network (HCCN), will be the keynote speaker on January ... Israel’s public health system. , The conference, “Hope and Resilience: ...
(Date:1/22/2015)... released a new blog post presenting a list of vehicles that ... , Some types of vehicles cannot be covered under an ordinary ... to see if their vehicle qualifies for auto insurance coverage. ... cars that cannot be covered by a plan. Clients have little ...
Breaking Medicine News(10 mins):Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
... (Sept. 20, 2007) A Jekyll-Hyde mechanism that both ... the basis for new cancer-fighting drugs. , Scientists in ... that a certain transcription factora protein that binds to ... genes on and offknown to aid in handling stresses ...
... scientist at Leeds whose research is challenging conventional thinking ... has secured funding to further investigate her findings. , ... Sciences has been awarded 80,000 from Heart Research UK ... affecting the heart muscle cell. , For ...
... the agency is doing , , THURSDAY, Sept. 20 ... prescription medicines for health, many are confused and distrustful ... new survey finds. , In fact, many of those ... and Drug Administration approves drugs, and almost half judged ...
... Developments in Solid Organ Transplantation, DALLAS, ... Review",is the focus of a one-day meeting ... Grapevine, Texas. Co-sponsored by the American Society ... Professionals,(NATCO), the conference agenda contains information about ...
... Increase ... SAN ANTONIO, Sept. 20 AT&T Inc. (NYSE: ... portfolio of radio frequency,identification (RFID) tracking offers for health ... operations of hospitals and other,health care facilities. AT&T ...
... MDA stunning discovery by German scientists may make blood ... as washing your hair. In the October print issue ... that the estimated 100,000 hair follicles on each persons ... EPO, the hormone primarily responsible for the creation of ...
Cached Medicine News:Health News:Heat shock proteins are co-opted for cancer 2Health News:Research to shed new light on how statins benefit heart patients 2Health News:Americans Confused About FDA and Drug Safety 2Health News:Americans Confused About FDA and Drug Safety 3Health News:Americans Confused About FDA and Drug Safety 4Health News:Dallas-Area Transplant Meeting Puts Spotlight on Key Issues 2Health News:AT&T Offers 'Network Industry-First' RFID Solution for Health Care Organizations 2Health News:AT&T Offers 'Network Industry-First' RFID Solution for Health Care Organizations 3Health News: New discovery leaves blood-doping athletes scratching their heads 2
... modular cleanroom for biological safety labs ... cleanliness (to Class 10/ISO 3) and ... create ultra-smooth surfaces that are easy ... radius corners simplify cleaning. Unique double-wall ...
Inquire...
Inquire...
Inquire...
Medicine Products: